Amicus Therapeutics (FOLD) Competitors $6.28 -0.03 (-0.48%) Closing price 04:00 PM EasternExtended Trading$6.27 -0.01 (-0.10%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. HALO, MDGL, RGEN, IONS, ALKS, LGND, BCRX, CLDX, DVAX, and INVAShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Halozyme Therapeutics Madrigal Pharmaceuticals Repligen Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva Amicus Therapeutics (NASDAQ:FOLD) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has higher valuation and earnings, FOLD or HALO? Halozyme Therapeutics has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.29M3.66-$56.11M-$0.09-69.78Halozyme Therapeutics$1.08B6.68$444.09M$3.7615.63 Do insiders & institutionals have more ownership in FOLD or HALO? 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, FOLD or HALO? Amicus Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Is FOLD or HALO more profitable? Halozyme Therapeutics has a net margin of 44.76% compared to Amicus Therapeutics' net margin of -5.41%. Halozyme Therapeutics' return on equity of 136.91% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-5.41% 4.67% 1.05% Halozyme Therapeutics 44.76%136.91%26.05% Do analysts recommend FOLD or HALO? Amicus Therapeutics currently has a consensus price target of $16.22, indicating a potential upside of 158.32%. Halozyme Therapeutics has a consensus price target of $62.70, indicating a potential upside of 6.69%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Amicus Therapeutics is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Halozyme Therapeutics 2 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media favor FOLD or HALO? In the previous week, Halozyme Therapeutics had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 7 mentions for Amicus Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.22 beat Amicus Therapeutics' score of 0.92 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHalozyme Therapeutics beats Amicus Therapeutics on 13 of the 16 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.94B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-69.7720.7327.9019.95Price / Sales3.66321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book9.668.308.635.90Net Income-$56.11M-$55.19M$3.24B$258.42M7 Day Performance-0.16%5.07%3.22%1.94%1 Month Performance9.98%17.61%10.72%12.02%1 Year Performance-39.32%7.03%34.94%20.81% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.0443 of 5 stars$6.28-0.5%$16.22+158.3%-38.8%$1.94B$528.29M-69.77480News CoverageUpcoming EarningsHALOHalozyme Therapeutics4.8494 of 5 stars$57.65+0.9%$62.50+8.4%+5.7%$7.10B$1.02B15.33390Positive NewsMDGLMadrigal Pharmaceuticals4.2717 of 5 stars$319.87+1.4%$420.63+31.5%+9.7%$7.10B$180.13M-17.7290Insider TradeRGENRepligen4.6091 of 5 stars$121.33-6.8%$170.75+40.7%-11.7%$6.82B$650.43M-269.621,778Upcoming EarningsAnalyst UpgradeAnalyst RevisionIONSIonis Pharmaceuticals4.572 of 5 stars$42.55+2.0%$58.25+36.9%-16.0%$6.77B$717.25M-14.231,069News CoverageUpcoming EarningsAnalyst RevisionALKSAlkermes4.7768 of 5 stars$29.69-1.9%$40.00+34.7%+8.8%$4.90B$1.51B14.211,800Upcoming EarningsAnalyst ForecastLGNDLigand Pharmaceuticals4.2568 of 5 stars$126.92+4.3%$147.17+16.0%+33.1%$2.45B$181.49M-17.8380BCRXBioCryst Pharmaceuticals4.5177 of 5 stars$8.96+2.3%$16.70+86.4%+15.3%$1.87B$450.71M-34.46530CLDXCelldex Therapeutics1.7927 of 5 stars$23.36+2.0%$50.11+114.5%-38.5%$1.55B$7.02M-8.65150DVAXDynavax Technologies4.3973 of 5 stars$10.74+1.5%$24.00+123.5%+3.7%$1.29B$294.62M-20.65350Positive NewsINVAInnoviva4.071 of 5 stars$19.58+4.3%$40.33+106.0%+8.2%$1.23B$358.71M-19.39100Upcoming Earnings Related Companies and Tools Related Companies HALO Alternatives MDGL Alternatives RGEN Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives CLDX Alternatives DVAX Alternatives INVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
